NVO Novo Nordisk A/S
- Official Name: Novo Nordisk A/S
- Headquarters: 800 Scudders Mill Road, PLAINSBORO, NJ 08536, US
- CEO: Lars Jorgensen
- Website: novonordisk.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Lost by 2.564 | (1.182) - 1.382 | ||
| 2025-07-15 | 1R | Lost by 1.938 | (2.019) - (0.081) | ||
| 2025-07-16 | 1R | Lost by 1.386 | (0.444) - 0.942 | ||
| 2025-07-22 | 2 | Lost by 3.178 | (2.159) - 1.019 | ||
| 2025-07-29 | 3 | Lost by 14.791 | (13.934) - 0.857 | ||
| 2025-08-05 | 4 | Won by 15.265 TOTW | 16.343 - 1.078 | ||
| 2025-08-12 | 5 | Won by 8.446 | 9.709 - 1.263 | ||
| 2025-08-19 | 6 | Won by 5.511 TOTW | 10.297 - 4.786 | ||
| 2025-08-26 | 7 | Won by 1.063 | 0.879 - (0.184) | ||
| 2025-09-02 | 8 | Lost by 0.650 | 1.874 - 2.524 | ||
| 2025-09-09 | 9 | Lost by 0.558 | (4.801) - (4.243) | ||
| 2025-09-16 | 10 | Won by 5.861 TOTW | 6.228 - 0.367 | ||
| 2025-09-23 | 11 | Won by 5.538 | 3.997 - (1.541) | ||
| 2025-09-30 | 12 | Lost by 11.395 | (7.175) - 4.220 | ||
| 2025-10-07 | 13 | Won by 5.969 | 5.887 - (0.082) | ||
| 2025-10-14 | 14 | Lost by 8.376 | (4.073) - 4.303 | ||
| 2025-10-21 | 15 | Lost by 2.487 | (3.541) - (1.054) |
Latest News
Yahoo - 2026-09-28
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulatio...
Yahoo - 2026-09-28
Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come
Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in freefall raise a real q...
Benzinga - 2026-09-28
Anthropic Claude’s Claimed Breakthrough in Biology Faces a Major Question — Scientist Says He Had Already Studied the Enzymes for 4 Years
Anthropic’s Claude enzyme discovery claim faces scrutiny after a biologist questioned whether prior research influenced the AI’s findings.
Yahoo - 2026-09-27
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Benzinga - 2026-09-27
Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries
New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic ...
Yahoo - 2026-09-27
Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?
A stock that has lost more than 70% of its value from the peak tends to invite hard questions, and Novo Nordisk A/S (NYSE:NVO) is now facing them from...
Yahoo - 2026-09-27
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squib...
Yahoo - 2026-09-27
Novo’s Pipeline Strategy Takes Another Step Forward
Novo Nordisk A/S (NYSE:NVO) has signed a drug-discovery and licensing agreement with Orbis Medicines worth up to $1.4 billion to develop oral therapie...
Yahoo - 2026-09-27
Novo Nordisk Searches for Growth Beyond its Biggest Franchise
Novo Nordisk A/S (NYSE:NVO) is defending its push to diversify beyond obesity as CEO Mike Doustdar signals that the company is willing to pursue deals...
SeekingAlpha - 2026-09-27
Earn 10-15% Potential Income: Monthly Options Series (Oct. 2026)
Build a disciplined options income strategy targeting 12â15% annually. Read the full analysis here.
Yahoo - 2026-09-26
What Is Novo Nordisk (CPSE:NOVO B) Getting From A €1.165 Billion Licensing Deal?
Novo Nordisk (CPSE:NOVO B) agreed a €1.165b global licensing deal with Swedish drug delivery specialist Nanexa for long-acting injectables. The coll...
Yahoo - 2026-09-26
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
Benzinga - 2026-09-26
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is struggling to keep pace.
Yahoo - 2026-09-26
Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s vi...
Yahoo - 2026-09-25
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
SeekingAlpha - 2026-09-25
InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair
InMode (INMD) stays rangebound as US sales slip; global growth and consumables stabilize. Read here for a detailed investment analysis.
Yahoo - 2026-09-25
Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
The drugmaker badly needs more clinical wins.
Yahoo - 2026-09-25
Viatris sues Novo Nordisk over generic Wegovy patent dispute
Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version o...
Yahoo - 2026-09-25
Novo Nordisk Changed the World With Its GLP-1 Weight-Loss Drugs. Now It Wants to Help Cure Baldness.
The Danish pharmaceutical giant that brought the world Ozempic may be ready to start researching a cure for hair loss. From a business perspective, it...
Yahoo - 2026-09-25
European Markets Close Mostly Higher Friday on Hopes for US-Iran Strait Deal
European stock markets closed mostly higher in Friday trading as oil prices fell amid hopes of a pos
Yahoo - 2026-09-25
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.
Benzinga - 2026-09-25
What's Going on With Novo Nordisk Stock on Friday?
Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.
Yahoo - 2026-09-25
Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem
The collaboration covers up to five programs in obesity, diabetes and other cardiometabolic diseases.
Yahoo - 2026-09-25
Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
Nanexa's shares more than doubled
Yahoo - 2026-09-25
Novo Nordisk signs $1.3 billion deal for long-acting obesity shots
The agreement gives Novo exclusive rights to Swedish startup Nanexa's drug-coating technology for up to 5 programs targeting obesity and diabetes
Benzinga - 2026-09-25
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transac...
Yahoo - 2026-09-25
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact t...
Yahoo - 2026-09-25
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The biotech player could eventually rival big pharma companies.
Yahoo - 2026-09-25
Novo Nordisk Licenses Nanexa Drug-Delivery Technology in Deal Worth Up to €1.17 Billion
Novo Nordisk (NYSE:NVO) has agreed to license drug-delivery technology from Swedish biotechnology company Nanexa in an agreement potentially worth up ...
Yahoo - 2026-09-25
Nanexa shares rocket 114% on $1.3 billion Novo Nordisk licensing deal
Investing.com -- Shares of Nanexa surged more than 110% in early Friday trading after the Swedish drug-delivery company announced a global licensing a...
Yahoo - 2026-09-25
Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, the latest in a string of small acquisition...
Yahoo - 2026-09-24
Novo Nordisk's CEO delivered a warning that sank its stock by 8%
CEO Mike Doustdar spoke openly about a risk facing Wegovy and Ozempic, and Wall Street’s growth expectations for Novo shifted quickly.
Yahoo - 2026-09-24
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells ...
Yahoo - 2026-09-24
Novo Nordisk (NVO) Sets Pipeline Sales Target Above $23 Billion By 2035
Novo Nordisk (NYSE:NVO) outlined new long term growth ambitions and patent transition plans for semaglutide in a recent investor update. Management de...
Yahoo - 2026-09-24
European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower Thur
SeekingAlpha - 2026-09-24
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
Yahoo - 2026-09-23
Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know
Novo Nordisk (NVO) closed the most recent trading day at $38.17, moving 3.12% from the previous trading session.
Yahoo - 2026-09-23
Novo Nordisk CEO opens the door to major move for U.S. investors
The U.S. now accounts for more than half of Novo Nordisk’s revenue.
Yahoo - 2026-09-23
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
NVO stock is down 11% this week, on track for its worst week since late February if losses hold.
Yahoo - 2026-09-23
Novo's Oral Wegovy Just Revealed a Surprising Weight-Loss Signal
Recent weight gain was associated with a higher likelihood of losing at least 10% of body weight.
Yahoo - 2026-09-23
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 resu...
Benzinga - 2026-09-23
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
Yahoo - 2026-09-23
Novo Nordisk open to direct New York listing, CEO says
Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, ...
Show more
Yahoo - 2026-09-23
Huge News For Novo Nordisk Fans
Yahoo - 2026-09-23
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
Yahoo - 2026-09-23
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Yahoo - 2026-09-23
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Yahoo - 2026-09-23
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Yahoo - 2026-09-23
The Stock Market Is Sleeping on the Next Big AI Catalyst
Yahoo - 2026-09-23
U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast
Yahoo - 2026-09-23
Novo Nordisk CEO Says Company Open to Direct NYSE Share Listing
SeekingAlpha - 2026-09-23
Launching The Allocation Compass: A Risk-Reward Approach To Portfolio Allocation
SeekingAlpha - 2026-09-23
Novo Nordisk: A Cheap Multiple Can't Fix Poor Growth
Yahoo - 2026-09-23
Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver Ailments
Benzinga - 2026-09-23
Anthropic, OpenEvidence Expand Free AI Clinical Tool to 100 Countries: Report
Benzinga - 2026-09-23
'Ozempic Maker Novo Open to Upgrading New York Listing' - FT
Yahoo - 2026-09-22
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Yahoo - 2026-09-22
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
Yahoo - 2026-09-22
VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
Yahoo - 2026-09-22
Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch
Yahoo - 2026-09-22
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
Yahoo - 2026-09-22
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
Yahoo - 2026-09-22
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Yahoo - 2026-09-22
European Markets Close Mixed Ahead of Trump-Xi Summit; Saudi Arabia Oil Pipeline Restarts
Yahoo - 2026-09-22
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Yahoo - 2026-09-22
Company News for Sep 22, 2026
Yahoo - 2026-09-22
Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial
Benzinga - 2026-09-22
3 Health Care Stocks With Whale Alerts In Today’s Session
Yahoo - 2026-09-22
VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance
Yahoo - 2026-09-22
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
Yahoo - 2026-09-22
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?
Benzinga - 2026-09-22
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Yahoo - 2026-09-22
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Yahoo - 2026-09-21
Novo Nordisk (CPSE:NOVO B) Unveiled A 2030 Blockbuster Drug Plan
SeekingAlpha - 2026-09-21
Novo Nordisk A/S (NOVO:CA) Analyst/Investor Day Transcript
Yahoo - 2026-09-21
LLY Stock Gains As CEO Says Foundayo Wins One-Third of New GLP-1 Pill Starts, Breaks Ground On $6.5B Houston Plant
Yahoo - 2026-09-21
Sector Update: Healthcare Stocks Higher Late Afternoon
Yahoo - 2026-09-21
Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round
Yahoo - 2026-09-21
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction
Yahoo - 2026-09-21
Why Novo Stock Is Tumbling After Drugmaker Unveils Ambitious Growth Plan
Yahoo - 2026-09-21
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Yahoo - 2026-09-21
Why Novo Nordisk Stock Just Crashed
Yahoo - 2026-09-21
European Stocks Close Higher Monday as Oil Prices Tumble
Yahoo - 2026-09-21
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Yahoo - 2026-09-21
Novo’s Big 2030 Pitch Gets a Small Reception
Yahoo - 2026-09-21
European Equities Traded in the US as American depositary Receipts Rise in Monday Trading
Yahoo - 2026-09-21
Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
Yahoo - 2026-09-21
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
Yahoo - 2026-09-21
Accenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround | Stock Movers
Yahoo - 2026-09-21
Bitcoin prices, Logan & Jake Paul, Jensen Huang talks human survival: 3 crazy market movers
Yahoo - 2026-09-21
Why Novo Nordisk investors feel disappointed today
Benzinga - 2026-09-21
10 Health Care Stocks Whale Activity In Today’s Session
Benzinga - 2026-09-21
Crude Oil Down 4%; Intel Shares Move Higher
Yahoo - 2026-09-21
Novo Nordisk Targets Over Five New Blockbusters By 2030, But NVO Stock Slides On Growth Concerns
Yahoo - 2026-09-21
Novo Nordisk stock falls after 2030 strategy disappoints investors
Benzinga - 2026-09-21
At Novo Nordisk Capital Markets Day, Co CFO Says Reasonable To Expect That We Should Be Able To Grow The Company By Mid-Single Digits Compound Annual Growth Rate Toward 2030
Benzinga - 2026-09-21
At Novo Nordisk Capital Markets Day, Co CFO Says Aim To Maintain Broadly Stable Operating Margin Until 2030 Compared To Today
Yahoo - 2026-09-21
Novo Plunges as Investors Seek More Robust Sales Targets
Yahoo - 2026-09-21
Novo Nordisk stock gets drilled on pipeline concerns— its CEO sees this as the main problem
Benzinga - 2026-09-21
Beyond Ozempic: Novo Nordisk Plots Next Decade Growth with Bigger Pipeline, Slimmer Workforce
Yahoo - 2026-09-21
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
Benzinga - 2026-09-21
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Yahoo - 2026-09-21
Highlights to be presented at Novo’s Capital Markets Day 2026
Benzinga - 2026-09-21
Novo Nordisk Releases Topline Results From Phase 3 REIMAGINE 5 and REDEFINE 9 Trials Of Once-Weekly Cagrisema (Cagrilintide and Semaglutide)
Yahoo - 2026-09-21
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
Yahoo - 2026-09-20
The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?
Yahoo - 2026-09-19
What does the EU have that the U.S. does not?
Yahoo - 2026-09-19
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
SeekingAlpha - 2026-09-19
Under-Valued Dividend Growers: 8 Stocks Averaging A 10.2x P/E
Yahoo - 2026-09-18
A drugmaker is gaining from the side effects of weight-loss drugs
Yahoo - 2026-09-18
Novo CEO Says Drugmaker Needs to “Rethink” its Obesity Strategy
Yahoo - 2026-09-18
Novo is Building a Strong Base to Address Unmet Needs in Diabetes and Obesity Drugs
Benzinga - 2026-09-18
Congressman Ditches Magnificent Seven Stocks for Consumer Staples: Here's What He Bought
Yahoo - 2026-09-18
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
Benzinga - 2026-09-18
Reported Earlier: Sandoz Canada Launches Lower-Cost Generic Version Of Novo Nordisk’s Ozempic, Expanding Access to Semaglutide for Type 2 Diabetes
SeekingAlpha - 2026-09-18
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation
Yahoo - 2026-09-18
Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
SeekingAlpha - 2026-09-18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Benzinga - 2026-09-18
CHMP of the European Medicines Agency Recommends Approving Novo Nordisk's Once-Weekly Sogroya for Children with Idiopathic Short Stature with Persistent Growth Disturbance
Yahoo - 2026-09-17
Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trials
Yahoo - 2026-09-17
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
Yahoo - 2026-09-17
Novo Nordisk's hemophilia drug clears a key hurdle in Europe
Yahoo - 2026-09-17
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
Yahoo - 2026-09-17
Sector Update: Healthcare Stocks Rise Thursday Afternoon
Yahoo - 2026-09-17
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Yahoo - 2026-09-17
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
Yahoo - 2026-09-17
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
Yahoo - 2026-09-17
Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
Yahoo - 2026-09-17
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
Yahoo - 2026-09-17
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Benzinga - 2026-09-17
EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy
Yahoo - 2026-09-17
Novo Nordisk Publishes Phase 3b Denecimig Results in Haemophilia A
SeekingAlpha - 2026-09-17
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Yahoo - 2026-09-17
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.
Yahoo - 2026-09-17
Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
Benzinga - 2026-09-17
Novo Nordisk Says EMA's CHMP Recommends EU Approval Of Haemophilia A Treatment FREHEMGO; Expects First European Launch In Q4 2026
Yahoo - 2026-09-17
This Trend is Excellent News for Eli Lilly and Its Investors
Yahoo - 2026-09-16
Why Novo Nordisk (NVO) Is Getting Attention Today
Yahoo - 2026-09-16
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
Yahoo - 2026-09-16
Novo Drops as Claude Enters Drug Development
Yahoo - 2026-09-16
Sector Update: Healthcare Stocks Edge Lower Late Afternoon
Yahoo - 2026-09-16
Novo Nordisk to Collaborate With Anthropic to Help Accelerate Drug Discovery, Development
Yahoo - 2026-09-16
Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.
SeekingAlpha - 2026-09-16
Novo Nordisk: Why This Corporate Rebrand Is More Than Simply PR Posturing
SeekingAlpha - 2026-09-16
Ascendis Pharma: Back To Full Independence
Yahoo - 2026-09-16
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says
Yahoo - 2026-09-16
Novo Nordisk Scores Major AI Deal With World's Most Valuable AI Company
Yahoo - 2026-09-16
Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know
Yahoo - 2026-09-16
Novo Nordisk partners with Anthropic to turbocharge drug discovery
Benzinga - 2026-09-16
Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug
Yahoo - 2026-09-16
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
Benzinga - 2026-09-16
Novo Nordisk, Anthropic Team Up For AI Drug Research
Yahoo - 2026-09-16
NVO To Present Fresh Data From Blockbuster Wegovy Pill At European Conference As Rival Eli Lilly Readies Its Own Obesity Updates
Benzinga - 2026-09-16
Novo Nordisk Announces Collaboration With Anthropic To Use Claude Science And Anthropic Models For Drug Discovery, Software Development
Yahoo - 2026-09-16
Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
Yahoo - 2026-09-15
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026
Yahoo - 2026-09-15
FDA clears first generic radioligand drug; Sionna turns to layoffs
Yahoo - 2026-09-15
Novo Nordisk Stock Falls After Major Rebrand
Yahoo - 2026-09-15
Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market
Benzinga - 2026-09-15
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Yahoo - 2026-09-15
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
Yahoo - 2026-09-15
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-09-15
Eli Lilly and Novo Nordisk have paid more than 270,000 doctors — one as much as $1M — to promote GLP-1 weight-loss drugs
Yahoo - 2026-09-15
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback
Yahoo - 2026-09-15
Novo Nordisk (CPSE:NOVO B) Rebrands As Novo In Consumer Health Push
Yahoo - 2026-09-15
Novo Nordisk (NVO) Unveils Global Rebrand As Novo
Yahoo - 2026-09-15
No Mo’ Nordisk: Ozempic Maker Rebrands as Novo, Promises New Culture
Yahoo - 2026-09-14
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Yahoo - 2026-09-14
Novo Nordisk Is Dropping Some Weight. Can a Rebrand Save the Stock?
Yahoo - 2026-09-14
NVO Stock Alert: What to Know as Novo Nordisk Rebrands to 'Novo'
Yahoo - 2026-09-14
No more Nordisk: Novo’s latest trim is in its name
Yahoo - 2026-09-14
Novo Nordisk Expands Wegovy’s Reach with China MASH Approval
Yahoo - 2026-09-14
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Yahoo - 2026-09-14
Novo Nordisk rebrands as Novo to compete in obesity market
Yahoo - 2026-09-14
Novo Nordisk Adopts Novo as Everyday Operating Name and Introduces New Cultural Framework
Yahoo - 2026-09-14
Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve
Yahoo - 2026-09-14
Ozempic-maker Novo Nordisk slims down to 'Novo'
Yahoo - 2026-09-14
NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To ‘Novo’ Amid Another Gloomy Year
Yahoo - 2026-09-14
Novo ditches Nordisk from name as drugmaker attempts revival
Yahoo - 2026-09-14
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
Benzinga - 2026-09-14
Novo Nordisk Just Dropped ‘Nordisk’ From Its Name as Obesity Drug Battle With Eli Lilly Heats Up — Here’s Why
SeekingAlpha - 2026-09-14
Wall Street Breakfast Podcast: Oil's New Chokepoint
Benzinga - 2026-09-14
Reported Earlier, Novo Nordisk Launches Rebrand Centered On ‘Lasting Health Starts Now’ And One-Word Name ‘Novo’
Yahoo - 2026-09-13
Morgan Stanley drops blunt verdict on Ozempic maker
Yahoo - 2026-09-13
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Yahoo - 2026-09-12
Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test
Yahoo - 2026-09-11
Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Yahoo - 2026-09-11
Could This New Opportunity Be Worth Billions for Novo Nordisk?
Yahoo - 2026-09-11
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
Yahoo - 2026-09-11
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
Yahoo - 2026-09-11
Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset
Yahoo - 2026-09-11
JPMorgan cautious on Hims & Hers on GLP-1 transition risk
Yahoo - 2026-09-11
NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity
Benzinga - 2026-09-11
This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday
Benzinga - 2026-09-11
Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40
Yahoo - 2026-09-10
Novo Stays Flat as Wegovy Wins China's First GLP-1 MASH Label
Yahoo - 2026-09-10
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
SeekingAlpha - 2026-09-10
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety
Yahoo - 2026-09-10
Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
Yahoo - 2026-09-10
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
SeekingAlpha - 2026-09-10
Pfizer: Firing On All Cylinders
Benzinga - 2026-09-10
China Approves Novo Nordisk's Wegovy As First And Only GLP-1 RA Treatment For MASH
Yahoo - 2026-09-09
Can Oral Wegovy Help Novo Nordisk Capture China’s $4.46 Billion GLP-1 Opportunity?
Yahoo - 2026-09-09
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
Yahoo - 2026-09-08
Sector Update: Healthcare Stocks Fall Late Afternoon
Yahoo - 2026-09-08
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Yahoo - 2026-09-08
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Yahoo - 2026-09-08
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
Yahoo - 2026-09-08
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now
Benzinga - 2026-09-08
Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness
SeekingAlpha - 2026-09-08
Novo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted (Rating Downgrade)
SeekingAlpha - 2026-09-08
Wall Street Breakfast Podcast: Canada's Tariffs Go Live
Yahoo - 2026-09-07
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other.
Yahoo - 2026-09-07